CWA
NBIX icon

Clarus Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Clarus Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,766
Closed -$253K – 128
2024
Q4 		$253K Buy
+1,766
New +$218K 0.13% 106
2024
Q3 		– Sell
-1,740
Closed -$256K – 137
2024
Q2 		$256K Buy
1,740
+250
+17% +$34.3K 0.14% 107
2024
Q1 		$206K Sell
1,490
-352
-19% -$48.1K 0.12% 123
2023
Q4 		$252K Buy
+1,842
New +$212K 0.15% 100
2019
Q3 		– Sell
-802
Closed -$68K – 414
2019
Q2 		$68K Buy
802
+608
+313% +$49.9K 0.05% 241
2019
Q1 		$17K Hold
194
– – 0.01% 447
2018
Q4 		$14K Buy
194
+97
+100% +$9.29K 0.02% 461
2018
Q3 		$12K Buy
+97
New +$11K 0.01% 516

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clarus Wealth Advisors's NBIX Position: Q1 2025 in Review

Clarus Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 1,766 shares — an estimated $253K sold.

Clarus Wealth Advisors first reported a position in NBIX in Q3 2018 and held it in 8 quarters. The position peaked at $256K in Q2 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Clarus Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Clarus Wealth Advisors sold 1,766 Neurocrine Biosciences shares in Q1 2025, an estimated $253K.
  • Clarus Wealth Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 8 quarters.
  • Clarus Wealth Advisors's Neurocrine Biosciences position peaked at $256K in Q2 2024.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Clarus Wealth Advisors's 13F filing for Q1 2025, filed 10 Apr 2025.